Cervarix is a vaccine for use from the age of 9 years for the prevention of pre-malignant genital lesions and cervical cancer causally related to certain oncogenic human papilloma virus (HPV) types.1
- Cervarix IPI Version number: GDS024/ IPI019 / Date of issue: 02/Mar/15 2015 GSK group of companies
- Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89–99.
- GLOBOCAN. Cervical Cancer Incidence and Mortality Worldwide in 2012: Cancer Fact Sheet. Available at: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp. Last accessed February 2017.
- American Cancer Society - Cervical cancer? Available at: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-what-is-cervical-cancer. Last accessed February 2017.